Home > Publications Database > Prognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation. > print

001     274050
005     20250119000259.0
024 7 _ |a 10.1111/ene.16581
|2 doi
024 7 _ |a pmid:39714176
|2 pmid
024 7 _ |a pmc:PMC11664725
|2 pmc
024 7 _ |a 1351-5101
|2 ISSN
024 7 _ |a 1468-1331
|2 ISSN
024 7 _ |a altmetric:172348960
|2 altmetric
037 _ _ |a DZNE-2025-00031
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Barba, Lorenzo
|0 0000-0003-1328-3620
|b 0
245 _ _ |a Prognostic serum biomarkers of synaptic, neuronal and glial injury in patients with acute ischemic stroke of the anterior circulation.
260 _ _ |a Oxford [u.a.]
|c 2025
|b Wiley-Blackwell
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1736940440_5558
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a We aimed to investigate the prognostic role of β-synuclein in comparison to that of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) for predicting functional outcome after acute ischemic stroke (AIS).We measured serum concentrations of β-synuclein, NfL and GFAP 24 h after hospital admission in 213 consecutive patients with moderate-to-severe AIS. We investigated the association between serum biomarkers and radiological/clinical characteristics, 3-months mortality and functional outcome on the modified Rankin Scale (mRS).In 213 patients with AIS [mean age: 76.1 (±12.5) years, 53.1% males, median NIHSS score on admission: 13 (IQR: 9-17)], higher levels of β-synuclein, NfL and GFAP were associated with higher NIHSS scores and with lower Alberta Stroke Program CT Score (ASPECTS) points on admission. Serum β-synuclein levels was significantly correlated with NfL (rho = 0.715, p < 0.001) and GFAP concentrations (rho = 0.684, p < 0.001). The inclusion of serum β-synuclein significantly improved the accuracy of prediction models without biomarkers for overall mortality (AUC: 0.836 vs. 0.752, p < 0.001) and mRS 3-6 vs. 0-2 (AUC: 0.812 vs. 0.624, p < 0.001). Combination models with NfL and/or GFAP showed a similar accuracy.Serum β-synuclein may be used to assess synaptic damage/dysfunction and to predict 3-months clinical outcomes in patients with AIS.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a GFAP
|2 Other
650 _ 7 |a NfL
|2 Other
650 _ 7 |a beta‐synuclein
|2 Other
650 _ 7 |a biomarkers
|2 Other
650 _ 7 |a stroke
|2 Other
650 _ 7 |a Biomarkers
|2 NLM Chemicals
650 _ 7 |a Glial Fibrillary Acidic Protein
|2 NLM Chemicals
650 _ 7 |a neurofilament protein L
|2 NLM Chemicals
650 _ 7 |a Neurofilament Proteins
|2 NLM Chemicals
650 _ 7 |a GFAP protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Biomarkers: blood
|2 MeSH
650 _ 2 |a Ischemic Stroke: blood
|2 MeSH
650 _ 2 |a Ischemic Stroke: mortality
|2 MeSH
650 _ 2 |a Prognosis
|2 MeSH
650 _ 2 |a Aged, 80 and over
|2 MeSH
650 _ 2 |a Glial Fibrillary Acidic Protein: blood
|2 MeSH
650 _ 2 |a Neurofilament Proteins: blood
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Neuroglia
|2 MeSH
650 _ 2 |a Neurons: pathology
|2 MeSH
650 _ 2 |a Synapses
|2 MeSH
700 1 _ |a Vollmuth, Christoph
|0 0000-0002-5893-1196
|b 1
700 1 _ |a Halbgebauer, Steffen
|0 P:(DE-2719)9002026
|b 2
|u dzne
700 1 _ |a Ungethüm, Kathrin
|b 3
700 1 _ |a Hametner, Christian
|b 4
700 1 _ |a Essig, Fabian
|b 5
700 1 _ |a Kollikowski, Alexander M
|b 6
700 1 _ |a Pham, Mirko
|0 0000-0003-1295-2685
|b 7
700 1 _ |a Schuhmann, Michael K
|b 8
700 1 _ |a Heuschmann, Peter U
|b 9
700 1 _ |a Oeckl, Patrick
|0 P:(DE-2719)9001560
|b 10
|u dzne
700 1 _ |a Steinacker, Petra
|b 11
700 1 _ |a Romoli, Michele
|b 12
700 1 _ |a D'Anna, Lucio
|b 13
700 1 _ |a Abu-Rumeileh, Samir
|0 0000-0003-0631-8506
|b 14
700 1 _ |a Haeusler, Karl Georg
|b 15
700 1 _ |a Stoll, Guido
|b 16
700 1 _ |a Neugebauer, Hermann
|b 17
700 1 _ |a Otto, Markus
|0 0000-0003-4273-4267
|b 18
773 _ _ |a 10.1111/ene.16581
|g Vol. 32, no. 1, p. e16581
|0 PERI:(DE-600)2020241-6
|n 1
|p e16581
|t European journal of neurology
|v 32
|y 2025
|x 1351-5101
856 4 _ |u https://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.docx
856 4 _ |y OpenAccess
|u https://pub.dzne.de/record/274050/files/DZNE-2025-00031.pdf
856 4 _ |u https://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.doc
856 4 _ |u https://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.odt
856 4 _ |u https://pub.dzne.de/record/274050/files/DZNE-2025-00031%20SUP.pdf
856 4 _ |y OpenAccess
|x pdfa
|u https://pub.dzne.de/record/274050/files/DZNE-2025-00031.pdf?subformat=pdfa
909 C O |o oai:pub.dzne.de:274050
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 2
|6 P:(DE-2719)9002026
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9001560
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2023-10-22
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b EUR J NEUROL : 2022
|d 2023-10-22
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2023-10-22
|w ger
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2023-10-22
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2023-10-22
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b EUR J NEUROL : 2022
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2023-10-22
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2023-10-22
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 0
920 1 _ |0 I:(DE-2719)5000073
|k AG Öckl
|l Translational Mass Spectrometry and Biomarker Research
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)5000077
980 _ _ |a I:(DE-2719)5000073
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21